TAKO MEMRIEffects of Heart Failure Therapy on Manganese-Enhanced MRI Scans in Takotsubo Cardiomyopathy

Takotsubo cardiomyopathy is a heart condition that often mimics a heart attack, typically triggered by physical or emotional stress. It predominantly affects women aged between 50 and 74. Despite initial beliefs that this condition improves within weeks, 1 in 10 patients may not survive hospitalization, and those who recover have reduced long-term survival rates. Currently, there is no definitive treatment for this condition. This study aims to understand the long-term effects of Takotsubo cardiomyopathy and evaluate the impact of existing heart failure therapies on patients. The importance lies in potentially improving care and addressing the current lack of effective treatments for this condition. Participants in this study will be divided into two groups based on when they were diagnosed. Those diagnosed less than 3 months ago will receive either Bisoprolol, Valsartan, or no medication. Participants diagnosed more than 6 months ago will receive Sacubitril/Valsartan or Dapaglifozin for 3 months, followed by a switch to the alternative medication for another 3 months, with a 1-month break in between. Participants will attend regular study visits to assess the effects of the medication. These visits include various tests such as a manganese-enhanced MRI scan, an echocardiogram, an ECG, a walking test, and blood tests. Additionally, participants will have a clinical assessment by a study doctor and will be asked to complete a symptom questionnaire. The primary outcome measured is the uptake of manganese by the left ventricular heart muscle.